---
title: "TCT 2023: Initial phase of TRISCEND II trial of Evoque transcatheter replacement for severe tricuspid regurgitation meets primary endpoints"
date: "2023-10-26T18:30:43.000Z"
publishedDate: "26 octobre 2023"
summary: "A randomised trial comparing transcatheter tricuspid valve replacement (TTVR) with the Evoque system (Edwards Lifesciences) to medical therapy in patients with severe tricuspid regurgitation—TRISCEND II—has demonstrated “meaningful improvements in functional status and symptoms” at six months. This was the headline finding presented by Susheel Kodali (Columbia University Medical Center, New York, USA) during a late-breaking [&#8230;] The post TCT 2023: Initial phase of TRISCEND II trial of Evoque transcatheter replacement for severe tricuspid regurgitation meets primary endpoints appeared first on Cardiovascular News ."
importance: ""
sourceUrl: "https://cardiovascularnews.com/tct-2023-initial-phase-of-triscend-ii-trial-of-evoque-transcatheter-replacement-for-severe-tricuspid-regurgitation-meets-primary-endpoints/"
tags: ["France", "Actualité", "Cardiovascular News — Latest"]
permalink: "/papers/2023-10-26-tct-2023-initial-phase-of-triscend-ii-trial-of-evoque-transcatheter-replacement-for-severe-tricuspid-regurgitation-meets-primary-endpoints"
imageUrl: "https://cardiovascularnews.com/wp-content/uploads/sites/14/2023/10/IMG_7959.jpg"
imageCredit: "Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/tct-2023-initial-phase-of-triscend-ii-trial-of-evoque-transcatheter-replacement-for-severe-tricuspid-regurgitation-meets-primary-endpoints/"
---

![TCT 2023: Initial phase of TRISCEND II trial of Evoque transcatheter replacement for severe tricuspid regurgitation meets primary endpoints](https://cardiovascularnews.com/wp-content/uploads/sites/14/2023/10/IMG_7959.jpg)

*Crédit image : Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/tct-2023-initial-phase-of-triscend-ii-trial-of-evoque-transcatheter-replacement-for-severe-tricuspid-regurgitation-meets-primary-endpoints/*

## L’essentiel

A randomised trial comparing transcatheter tricuspid valve replacement (TTVR) with the Evoque system (Edwards Lifesciences) to medical therapy in patients with severe tricuspid regurgitation—TRISCEND II—has demonstrated “meaningful improvements in functional status and symptoms” at six months. This was the headline finding presented by Susheel Kodali (Columbia University Medical Center, New York, USA) during a late-breaking [&#8230;] The post TCT 2023: Initial phase of TRISCEND II trial of Evoque transcatheter replacement for severe tricuspid regurgitation meets primary endpoints appeared first on Cardiovascular News .

## Lien source

https://cardiovascularnews.com/tct-2023-initial-phase-of-triscend-ii-trial-of-evoque-transcatheter-replacement-for-severe-tricuspid-regurgitation-meets-primary-endpoints/
